Research and Practice in Thrombosis and Haemostasis

(The median citation count of Research and Practice in Thrombosis and Haemostasis is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-06-01 to 2024-06-01.)
Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis353
A proposal for staging COVID‐19 coagulopathy76
Venous thromboembolism in critically Ill patients with COVID‐19: Results of a screening study for deep vein thrombosis73
Prothrombotic changes in patients with COVID‐19 are associated with disease severity and mortality67
Vaccine‐induced Immune Thrombocytopenia and Thrombosis (VITT)58
Sexism in the management of bleeding disorders56
Tranexamic acid evidence and controversies: An illustrated review50
Heparin‐induced thrombocytopenia with thrombosis in COVID‐19 adult respiratory distress syndrome49
Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients46
Thrombosis and coagulopathy in COVID‐19: An illustrated review46
The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study43
Potential role of platelets in COVID‐19: Implications for thrombosis40
Comparison of the coagulopathies associated with COVID‐19 and sepsis39
Randomized trials of therapeutic heparin for COVID‐19: A meta‐analysis38
Posters Abstracts36
Essential aspects of the follow‐up after acute pulmonary embolism: An illustrated review35
Anticoagulation practice patterns in COVID‐19: A global survey34
Protease‐activated receptors: An illustrated review32
The role of platelets in sepsis31
Validation of the IMPROVE‐DD risk assessment model for venous thromboembolism among hospitalized patients with COVID‐1931
Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)30
Global reporting of pulmonary embolism–related deaths in the World Health Organization mortality database: Vital registration data from 123 countries29
Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features28
Hormonal therapies and venous thrombosis: Considerations for prevention and management26
Pulmonary embolism during the COVID‐19 pandemic: Decline in diagnostic procedures and incidence at a university hospital25
The psychological impact of pulmonary embolism: A mixed‐methods study25
Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants24
Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE24
Blood clot contraction: Mechanisms, pathophysiology, and disease24
Visualizing thrombosis to improve thrombus resolution23
The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease23
Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation21
Patient‐relevant health outcomes for hemophilia care: Development of an international standard outcomes set21
Venous thromboembolism in multiple myeloma is associated with increased mortality21
Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment21
Impact of novel hemophilia therapies around the world21
Preventing venous thromboembolism in oncology practice: Use of risk assessment and anticoagulation prophylaxis20
Acquired von Willebrand syndrome in monoclonal gammopathy – A scoping review on hemostatic management20
Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting19
Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)19
Living with a “hemophilia‐free mind” – The new ambition of hemophilia care?19
Vascular thromboembolic events following COVID‐19 hospital discharge: Incidence and risk factors18
Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID‐19: The Swiss COVID‐HEP randomized clinical trial18
Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts18
Gender gap in women authors is not worse during COVID‐19 pandemic: Results from Research and Practice in Thrombosis and Haemostasis18
Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID‐19: Study design of the phase IIa STARS trial17
A call to action for anticoagulation stewardship17
Elevated von Willebrand factor levels during heavy menstrual bleeding episodes limit the diagnostic utility for von Willebrand disease17
Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma17
Viscoelastic testing: an illustrated review of technology and clinical applications16
Evaluation of different commercial antibodies for their ability to detect human and mouse tissue factor by western blotting16
A risk score for prediction of venous thromboembolism in gynecologic cancer: The Thrombogyn score15
Vaccine‐induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCOV19) vaccine–A case report15
Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern15
Direct oral anticoagulants for unusual‐site venous thromboembolism15
An illustrated review of bleeding assessment tools and common coagulation tests15
Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination15
Caging the dragon: Research approach to COVID‐19–related thrombosis15
DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples15
Platelets in the neonate: Not just a small adult14
Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status14
Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors14
Thrombotic microangiopathies: An illustrated review14
Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients14
High‐dose IVIG plus cangrelor platelet “anesthesia” during urgent heparin‐CPB in a patient with recent SRA‐negative HIT‐thrombosis with persisting platelet‐activating antibodies14
Anticoagulation after intracranial hemorrhage in brain tumors: Risk of recurrent hemorrhage and venous thromboembolism13
COVID‐19 and venous thromboembolism: A narrative review13
Core and shell platelets of a thrombus: A new microfluidic assay to study mechanics and biochemistry13
The intersection of vector biology, gene therapy, and hemophilia13
Diagnosis and follow‐up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay13
ST Genesia reference values of 117 healthy donors measured with STG‐BleedScreen, STG‐DrugScreen and STG‐ThromboScreen reagents13
A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding13
Novel mechanisms of thrombo-inflammation during infection: spotlight on neutrophil extracellular trap-mediated platelet activation13
Physical forces regulating hemostasis and thrombosis: Vessels, cells, and molecules in illustrated review13
Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study12
Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report12
Hemostasis and fibrinolysis in COVID‐19 survivors 6 months after intensive care unit discharge12
Fibrinolysis: an illustrated review12
Pulmonary embolism and deep vein thrombosis—comorbidities and temporary provoking factors in a register‐based study of 1.48 million people12
MG1113, a specific anti–tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia12
Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method12
The ongoing enigma of SARS‐CoV‐2 and platelet interaction12
Platelet‐leukocyte interactions in COVID‐19: Contributions to hypercoagulability, inflammation, and disease severity12
Patient selection for hemophilia gene therapy: Real‐life data from a single center11
The lived experience of women with a bleeding disorder: A systematic review11
The challenges of diagnosing heparin‐induced thrombocytopenia in patients with COVID‐1911
Venous thromboembolism after lower extremity orthopedic surgery: A population‐based nationwide cohort study11
Use of rotational thromboelastometry to predict hemostatic complications in pediatric patients undergoing extracorporeal membrane oxygenation: A retrospective cohort study11
Sex differences in flow cytometry–based platelet reactivity in stable outpatients suspected of myocardial ischemia11
Epidemiology of cerebral venous sinus thrombosis and cerebral venous sinus thrombosis with thrombocytopenia in the United States, 2018 and 201911
Respective roles of Glycoprotein VI and FcγRIIA in the regulation of αIIbβ3‐mediated platelet activation to fibrinogen, thrombus buildup, and stability11
Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study11
GPIbα is the driving force of hepatic thrombopoietin generation11
Building a better NET: Neutrophil extracellular trap targeted therapeutics in the treatment of infectious and inflammatory disorders11
D‐dimer testing in clinical practice in the era of COVID‐1911
The venous thrombosis registry in Østfold Hospital (TROLL registry) ‐ design and cohort description11
A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing11
Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review10
Liver fibrosis is driven by protease‐activated receptor‐1 expressed by hepatic stellate cells in experimental chronic liver injury10
Development of inhibitors in hemophilia A: An illustrated review10
Disseminated intravascular coagulation diagnosis: Positive predictive value of the ISTH score in a Danish population10
Deterioration of vaccine‐induced immune thrombotic thrombocytopenia treated by heparin and platelet transfusion: Insight from functional cytometry and serotonin release assay10
Racial differences in protein S Tokushima and two protein C variants as genetic risk factors for venous thromboembolism10
Second‐line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records10
Optimization of DOAC management services in a centralized anticoagulation clinic10
Health‐related quality‐of‐life questionnaires for deep vein thrombosis and pulmonary embolism: A systematic review on questionnaire development and methodology10
Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies10
Inhibition of platelet adhesion, thrombus formation, and fibrin formation by a potent αIIbβ3 integrin inhibitor from ticks10
Antiviral anticoagulation10
Severe COVID‐19 is associated with endothelial activation and abnormal glycosylation of von Willebrand factor in patients undergoing hemodialysis10
Neutrophil extracellular trap regulators in sickle cell disease: Modulation of gene expression of PADI4, neutrophil elastase, and myeloperoxidase during vaso‐occlusive crisis10
Global coagulation assays in patients with diabetes mellitus9
“If I wasn't a girl”: Experiences of adolescent girls with heavy menstrual bleeding and inherited bleeding disorders9
The contact activation system and vascular factors as alternative targets for Alzheimer's disease therapy9
Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trial9
Thrombin generation measured on ST Genesia, a new platform in the coagulation routine lab: Assessment of analytical and between‐subject variation9
Developing and optimizing a computable phenotype for incident venous thromboembolism in a longitudinal cohort of patients with cancer9
Reproductive issues in women on direct oral anticoagulants9
The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study9
Prevalence of thrombocytopenia, anti–platelet factor 4 antibodies and D‐dimer elevation in Thai people After ChAdOx1 nCoV‐19 vaccination9
2B von Willebrand disease diagnosis: Considerations reflecting on 2021 multisociety guidelines9
Fibrinogen concentrate for bleeding in patients with congenital fibrinogen deficiency: Observational study of efficacy and safety for prophylaxis and treatment9
Aspirin at 120: Retiring, recombining, or repurposing?9
Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation9
Generation and validation of small ADAMTS13 fragments for epitope mapping of anti‐ADAMTS13 autoantibodies in immune‐mediated thrombotic thrombocytopenic purpura9
D‐dimer, thrombin generation, and risk of a first venous thrombosis in the elderly9
Menstruation, anticoagulation, and contraception: VTE and uterine bleeding9
Direct Oral Anticoagulant removal by a DOAC filter: Impact on lupus anticoagulant testing – Evaluation on spiked and patient samples9
Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety9
Communication at diagnosis of venous thromboembolism: Lasting impact of verbal and nonverbal provider communication on patients9
Generic PROMIS item banks in adults with hemophilia for patient‐reported outcome assessment: Feasibility, measurement properties, and relevance8
Harnessing Twitter to empower scientific engagement and communication: The ISTH 2020 virtual congress experience8
Thromboprophylaxis for children hospitalized with COVID‐19 and MIS‐C8
Classification of von Willebrand disease in the context of modern contemporary von Willebrand factor testing methodologies8
Prevalence of anti–platelet factor 4/polyanionic antibodies after COVID‐19 vaccination with ChAdOx1 nCoV‐19 and CoronaVac in Thais8
Quality of life in adolescents with heavy menstrual bleeding: Validation of the Adolescent Menstrual Bleeding Questionnaire (aMBQ)8
Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy8
ChAdOx1 vaccination, blood coagulation, and inflammation: No effect on coagulation but increased interleukin‐68
Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM‐Line): A two‐center open‐label pilot randomized controlled trial8
Protease: Serpin complexes to assess contact system and intrinsic pathway activation8
Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre‐ and postinfusion samples8
Carbamazepine, phenytoin, and oral anticoagulants: Drug‐drug interaction and clinical events in a retrospective cohort8
Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette‐based survey8
Clinical relapse of immune‐mediated thrombotic thrombocytopenic purpura following COVID‐19 vaccination8
Sex‐specific aspects of venous thromboembolism: What is new and what is next?8
Acquired hemophilia following COVID‐19 vaccination: Case report and review of literature8
Anti‐platelet factor 4 immunoglobulin G levels in vaccine‐induced immune thrombocytopenia and thrombosis: Persistent positivity through 7 months8
Vaccine‐induced immune thrombotic thrombocytopenia presenting with normal platelet count8
How do anticoagulants impact menstrual bleeding and quality of life? - The PERIOD study8
Bleeding risks for uncharacterized platelet function disorders8
Improving diagnosis of von Willebrand disease: Reference ranges for von Willebrand factor multimer distribution8
Pulmonary embolism and deep venous thrombosis after COVID-19: long-term risk in a population-based cohort study8
Camelid‐derived single‐chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications8
Vaccine‐induced immune thrombotic thrombocytopenia with ChAdOx1 nCoV‐19 is rare in Asia8
Disparities in obstetric hemorrhage outcomes8
Measuring beta‐galactose exposure on platelets: Standardization and healthy reference values7
Annual report on equity, diversity, and inclusion: Research and Practice in Thrombosis and Haemostasis is meeting its goals7
Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study7
Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use7
Disruptive technology and hemophilia care: The multiple impacts of emicizumab7
Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune‐mediated thrombotic thrombocytopenic purpura in the United States7
Anticoagulation, immortality, and observations of COVID‐197
Endothelial cell activation, Weibel-Palade body secretion, and enhanced angiogenesis in severe COVID-197
A mixed‐methods study to evaluate a patient‐designed tool to reduce harm from cancer‐associated thrombosis: The EMPOWER study7
Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition7
Social determinants of health in pulmonary embolism management and outcome in hospitals: Insights from the United States nationwide inpatient sample7
Recanalization and outcomes after cerebral venous thrombosis: a systematic review and meta-analysis7
Blood and Bone: The quarantine chronicles7
Prostasin and hepatocyte growth factor B in factor VIIa generation: Serine protease knockdowns in zebrafish7
Coagulation biomarkers for ischemic stroke7
Epidemiology and 3‐year outcomes of combined oral contraceptive–associated distal deep vein thrombosis7
Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors7
Hemostatic phenotypes and genetic disorders7
Quantitative 3D microscopy highlights altered von Willebrand factor α‐granule storage in patients with von Willebrand disease with distinct pathogenic mechanisms7
Diversity, equity, and inclusion in publishing: Calling thrombosis and hemostasis journals to action in support of women7
The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste7
New and known predictors of the postthrombotic syndrome: A subanalysis of the ATTRACT trial7
Underrepresentation and undertreatment of women in hematology: An unsolved issue7
ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease7
Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin6
In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype6
Fitness enhances psychosocial well‐being and self‐confidence in young men with hemophilia: Results from Project GYM6
Tumor‐expressed microRNAs associated with venous thromboembolism in colorectal cancer6
Association between cardiovascular risk factors and venous thromboembolism in the elderly6
Antithrombin-lowering in hemophilia: a closer look at fitusiran6
Pulmonary embolism in acute lymphoblastic leukemia — An observational study of 1685 patients treated according to the NOPHO ALL2008 protocol6
Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study6
Fibrinolytic assays in bleeding of unknown cause: Improvement in diagnostic yield6
Interlaboratory variability of activated protein C resistance using the ETP‐based APC resistance assay6
Atrial fibrillation, venous thromboembolism, ischemic stroke, and all‐cause mortality: The Tromsø study6
MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID‐19 severe respiratory failure (MUST COVID): A retrospective cohort study6
Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting6
Assessing quality of life after pulmonary embolism: Comparing results from the PEmb‐QoL with semistructured interviews6
Rate zonal centrifugation can partially separate platelets from platelet‐derived vesicles6
COVID‐19 pandemic perspectives: A scientific silver lining?6
Hemostasis and tumor immunity6
Challenges and knowledge gaps facing hemophilia carriers today: Perspectives from patients and health care providers6
Mechanisms of cancer-associated thrombosis6
Sialic acid and platelet count regulation: Implications in immune thrombocytopenia6
eThrombosis: A new risk factor for venous thromboembolism in the pandemic era6
Characteristics and predictors of venous thrombosis recurrence in patients with cancer and catheter‐related thrombosis6
Using an electronic medical record patient portal for warfarin self-management: Empowering children and parents6
A microfluidic method to investigate platelet mechanotransduction under extensional strain6
Clinical significance of subsegmental pulmonary embolism: An ongoing controversy6
Anticoagulant drug‐drug interactions: Highlighting the need for antithrombotic stewardship and shared decision making6
Heparin-induced thrombocytopenia: An illustrated review6
Platelet reactivity and platelet count in women with iron deficiency treated with intravenous iron6
Thrombotic potential during pediatric acute lymphoblastic leukemia induction: Role of cell‐free DNA6
Compression stockings to prevent postthrombotic syndrome: Literature overview and presentation of the CELEST trial6
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B6
Magnetic resonance imaging in boys with severe hemophilia A: Serial and end‐of‐study findings from the Canadian Hemophilia Primary Prophylaxis Study6
Anticoagulation stewardship: Descriptive analysis of a novel approach to appropriate anticoagulant prescription6
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies6
Thrombosis and thromboembolism related to COVID‐19: A clarion call for obtaining solid estimates from large‐scale multicenter data6
Management of heavy menstrual bleeding in women with bleeding disorders in a tertiary care center6
The von Willebrand factor – ADAMTS‐13 axis in malaria6
Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study6
Fibronectin binding to von Willebrand factor occurs via the A1 domain6
Venous thromboembolism research priorities: A scientific statement from the American Heart Association and the International Society on Thrombosis and Haemostasis6
Risk of thrombosis with thrombocytopenia syndrome after COVID‐19 vaccination prior to the recognition of vaccine‐induced thrombocytopenia and thrombosis: A self‐controlled case series study in England6
Etiology and outcomes: Thrombotic microangiopathies in pregnancy6
Agreement of aptamer proteomics with standard methods for measuring venous thrombosis biomarkers6
Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia5
Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment—A report from ICTHIC 20215
Updating the Canadian Hemophilia Outcomes–Kids’ Life Assessment Tool (CHO‐KLAT) in the era of extended half‐life clotting factor concentrates5
Effects of thrombomodulin alfa on hemostatic parameters in disseminated intravascular coagulation: Post hoc analysis of a phase 3 randomized controlled trial5
Von Willebrand factor and the thrombophilia of severe COVID-19: in situ evidence from autopsies5
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study5
Cryo‐EM structures of coagulation factors5
Thrombosis in myeloproliferative neoplasms: Treatment outcomes of direct oral anticoagulants and vitamin K antagonists5
Tissue factor release following traumatic brain injury drives thrombin generation5
Evaluating hemostatic thresholds for neuraxial anesthesia in adults with hemorrhagic disorders and tendencies: A scoping review5
Recurrent thrombosis rescued by fondaparinux in high‐risk patients: A case series5
Thromboelastography determined dynamics of blood coagulation and its correlation with complications and outcomes in patients with coronavirus disease 20195
Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing5
Lupus anticoagulant associates with thrombosis in patients with COVID‐19 admitted to intensive care units: A retrospective cohort study5
Complement factor C4a does not activate protease‐activated receptor 1 (PAR1) or PAR4 on human platelets5
Evaluation of a new bead‐based assay to measure levels of human tissue factor antigen in extracellular vesicles in plasma5
Thrombosis and bleeding in patients with COVID-19 requiring extracorporeal membrane oxygenation: a systematic review and meta-analysis5
Left ventricular thrombus and pulmonary embolism: A case series of thrombosis in COVID‐19 in Thai patients5
Staying updated on COVID‐19: Social media to amplify science in thrombosis and hemostasis5
Poststroke venous thromboembolism and neutrophil activation: an illustrated review5
Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: A systematic review on efficacy and safety5
Improved efficacy/safety profile of factor XIa inhibitor BMS‐724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys5
Role of factor VIII, IX, and XI in venous thrombosis recurrence risk in adults and children: A systematic review5
Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 20215
Incorporating the patient voice and patient engagement in GOAL‐Hēm: Advancing patient‐centric hemophilia care5
Coagulation factor inhibitors in COVID‐19: From SARS‐CoV‐2 vaccination to infection5